Synthesis and assembly of Hepatitis B virus envelope protein-derived particles in Escherichia coli

Hao Li, Keisuke Onbe, Qiushi Liu, Masumi Iijima, Kenji Tatematsu, Masaharu Seno, Hiroko Tada, Shun’ ichi Kuroda

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Hepatitis B virus (HBV) envelope particles have been synthesized in eukaryotic cells (e.g., mammalian cells, insect cells, and yeast cells) as an HB vaccine immunogen and drug delivery system (DDS) nanocarrier. Many researchers had made attempts to synthesize the particles in Escherichia coli for minimize the cost and time for producing HBV envelope particles, but the protein was too deleterious to be synthesized in E. coli. In this study, we generated deletion mutants of HBV envelope L protein (389 amino acid residues (aa)) containing three transmembrane domains (TM1, TM2, TM3). The ΔNC mutant spanning from TM2 to N-terminal half of TM3 (from 237 aa to 335 aa) was found as a shortest form showing spontaneous particle formation. After the N-terminal end of ΔNC mutant was optimized by the N-end rule for E. coli expression, the modified ΔNC mutant (mΔNC) was efficiently expressed as particles in E. coli. The molecular mass of mΔNC particle was approx. 670 kDa, and the diameter was 28.5 ± 6.2 nm (mean ± SD, N = 61). The particle could react with anti-HBV envelope S protein antibody, indicating the particles exhibited S antigenic domain outside as well as HBV envelope particles. Taken together, the E. coli-derived mΔNC particles could be used as a substitute of eukaryotic cell-derived HBV envelope particles for versatile applications.

Original languageEnglish
Pages (from-to)155-160
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume490
Issue number2
DOIs
Publication statusPublished - Aug 19 2017

Fingerprint

Viral Envelope Proteins
Viruses
Hepatitis B virus
Escherichia coli
Virion
Eukaryotic Cells
Amino Acids
Cells
Molecular mass
Drug Delivery Systems
Yeast
Insects
Proteins
Vaccines
Yeasts
Research Personnel
Costs and Cost Analysis
Antibodies
Costs

Keywords

  • Bio-nanocapsule
  • Enveloped particles
  • Escherichia coli
  • Hepatitis B virus
  • Virus-like particle

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Synthesis and assembly of Hepatitis B virus envelope protein-derived particles in Escherichia coli. / Li, Hao; Onbe, Keisuke; Liu, Qiushi; Iijima, Masumi; Tatematsu, Kenji; Seno, Masaharu; Tada, Hiroko; Kuroda, Shun’ ichi.

In: Biochemical and Biophysical Research Communications, Vol. 490, No. 2, 19.08.2017, p. 155-160.

Research output: Contribution to journalArticle

Li, Hao ; Onbe, Keisuke ; Liu, Qiushi ; Iijima, Masumi ; Tatematsu, Kenji ; Seno, Masaharu ; Tada, Hiroko ; Kuroda, Shun’ ichi. / Synthesis and assembly of Hepatitis B virus envelope protein-derived particles in Escherichia coli. In: Biochemical and Biophysical Research Communications. 2017 ; Vol. 490, No. 2. pp. 155-160.
@article{e9bcb138c9ab486b8fc95013b6d6aae1,
title = "Synthesis and assembly of Hepatitis B virus envelope protein-derived particles in Escherichia coli",
abstract = "Hepatitis B virus (HBV) envelope particles have been synthesized in eukaryotic cells (e.g., mammalian cells, insect cells, and yeast cells) as an HB vaccine immunogen and drug delivery system (DDS) nanocarrier. Many researchers had made attempts to synthesize the particles in Escherichia coli for minimize the cost and time for producing HBV envelope particles, but the protein was too deleterious to be synthesized in E. coli. In this study, we generated deletion mutants of HBV envelope L protein (389 amino acid residues (aa)) containing three transmembrane domains (TM1, TM2, TM3). The ΔNC mutant spanning from TM2 to N-terminal half of TM3 (from 237 aa to 335 aa) was found as a shortest form showing spontaneous particle formation. After the N-terminal end of ΔNC mutant was optimized by the N-end rule for E. coli expression, the modified ΔNC mutant (mΔNC) was efficiently expressed as particles in E. coli. The molecular mass of mΔNC particle was approx. 670 kDa, and the diameter was 28.5 ± 6.2 nm (mean ± SD, N = 61). The particle could react with anti-HBV envelope S protein antibody, indicating the particles exhibited S antigenic domain outside as well as HBV envelope particles. Taken together, the E. coli-derived mΔNC particles could be used as a substitute of eukaryotic cell-derived HBV envelope particles for versatile applications.",
keywords = "Bio-nanocapsule, Enveloped particles, Escherichia coli, Hepatitis B virus, Virus-like particle",
author = "Hao Li and Keisuke Onbe and Qiushi Liu and Masumi Iijima and Kenji Tatematsu and Masaharu Seno and Hiroko Tada and Kuroda, {Shun’ ichi}",
year = "2017",
month = "8",
day = "19",
doi = "10.1016/j.bbrc.2017.06.015",
language = "English",
volume = "490",
pages = "155--160",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Synthesis and assembly of Hepatitis B virus envelope protein-derived particles in Escherichia coli

AU - Li, Hao

AU - Onbe, Keisuke

AU - Liu, Qiushi

AU - Iijima, Masumi

AU - Tatematsu, Kenji

AU - Seno, Masaharu

AU - Tada, Hiroko

AU - Kuroda, Shun’ ichi

PY - 2017/8/19

Y1 - 2017/8/19

N2 - Hepatitis B virus (HBV) envelope particles have been synthesized in eukaryotic cells (e.g., mammalian cells, insect cells, and yeast cells) as an HB vaccine immunogen and drug delivery system (DDS) nanocarrier. Many researchers had made attempts to synthesize the particles in Escherichia coli for minimize the cost and time for producing HBV envelope particles, but the protein was too deleterious to be synthesized in E. coli. In this study, we generated deletion mutants of HBV envelope L protein (389 amino acid residues (aa)) containing three transmembrane domains (TM1, TM2, TM3). The ΔNC mutant spanning from TM2 to N-terminal half of TM3 (from 237 aa to 335 aa) was found as a shortest form showing spontaneous particle formation. After the N-terminal end of ΔNC mutant was optimized by the N-end rule for E. coli expression, the modified ΔNC mutant (mΔNC) was efficiently expressed as particles in E. coli. The molecular mass of mΔNC particle was approx. 670 kDa, and the diameter was 28.5 ± 6.2 nm (mean ± SD, N = 61). The particle could react with anti-HBV envelope S protein antibody, indicating the particles exhibited S antigenic domain outside as well as HBV envelope particles. Taken together, the E. coli-derived mΔNC particles could be used as a substitute of eukaryotic cell-derived HBV envelope particles for versatile applications.

AB - Hepatitis B virus (HBV) envelope particles have been synthesized in eukaryotic cells (e.g., mammalian cells, insect cells, and yeast cells) as an HB vaccine immunogen and drug delivery system (DDS) nanocarrier. Many researchers had made attempts to synthesize the particles in Escherichia coli for minimize the cost and time for producing HBV envelope particles, but the protein was too deleterious to be synthesized in E. coli. In this study, we generated deletion mutants of HBV envelope L protein (389 amino acid residues (aa)) containing three transmembrane domains (TM1, TM2, TM3). The ΔNC mutant spanning from TM2 to N-terminal half of TM3 (from 237 aa to 335 aa) was found as a shortest form showing spontaneous particle formation. After the N-terminal end of ΔNC mutant was optimized by the N-end rule for E. coli expression, the modified ΔNC mutant (mΔNC) was efficiently expressed as particles in E. coli. The molecular mass of mΔNC particle was approx. 670 kDa, and the diameter was 28.5 ± 6.2 nm (mean ± SD, N = 61). The particle could react with anti-HBV envelope S protein antibody, indicating the particles exhibited S antigenic domain outside as well as HBV envelope particles. Taken together, the E. coli-derived mΔNC particles could be used as a substitute of eukaryotic cell-derived HBV envelope particles for versatile applications.

KW - Bio-nanocapsule

KW - Enveloped particles

KW - Escherichia coli

KW - Hepatitis B virus

KW - Virus-like particle

UR - http://www.scopus.com/inward/record.url?scp=85020652925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020652925&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2017.06.015

DO - 10.1016/j.bbrc.2017.06.015

M3 - Article

VL - 490

SP - 155

EP - 160

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -